RESEARCH: CANCER
FOLDING PROJECT #16470 PROFILE

Scientists want to understand how medicine works at the atomic level! They're studying RIPK2, a protein involved in cancer, and its interaction with inhibitors. By simulating RIPK2 with different inhibitors, they hope to figure out how these inhibitors block RIPK2 from binding to another protein called XIAP, which could lead to better cancer treatments.

Note: This TLDR is a simplication and may not be 100% accurate.

Kinases are a major target for a variety of cancer therapies, but their mechanism of action is relatively unknown at a detailed atomic level, preventing us from understanding and optimizing known inhibitors.

One example is the Serine/Threonine Kinase RIPK2.

RIPK2 inhibition is useful for cancer targeting as it prevents RIPK2 from binding a protein partner named XIAP.

In fact, there are already 3 known inhibitors that bind to RIPK2 and prevent RIPK2-XIAP binding! However, it remains difficult to optimize these ligands for clinical purposes because we do not understand how any of these three inhibitors actually act on RIPK2 to prevent XIAP binding behavior.

These four projects are simulating RIPK2 by itself and bound to each of the three inhibitors, with the hope that this will reveal a more detailed mechanism of how each inhibitor works to prevent XIAP binding.

As a bonus, this will help reveal how RIPK2 *binds* XIAP (also unknown)! In this set of projects we are studying the following systems: 16466 – RIPK2 16467 – RIPK2:CSLP43 inhibitor-bound complex 16468 – RIPK2:CSLP48 inhibitor-bound complex 16469 – RIPK2:GSK583 inhibitor-bound complex 16470 – RIPK2:WEHI-345 inhibitor-bound complex.

---

Kinases

Enzymes that transfer phosphate groups

Kinases are a crucial type of enzyme that play a vital role in various cellular processes. They add phosphate groups to other molecules, which can activate or deactivate them, influencing cell growth, signaling, and metabolism. Many diseases, including cancer, are linked to dysregulated kinase activity.

---

RIPK2

Receptor-interacting protein kinase 2

RIPK2 is a protein kinase involved in the innate immune response. It plays a crucial role in detecting pathogens and triggering inflammatory signaling pathways. Overactivation of RIPK2 has been implicated in various autoimmune diseases, while its inhibition shows promise as a therapeutic strategy for cancer and inflammatory disorders.

---

Inhibitors

Molecules that block the activity of enzymes or proteins

Inhibitors are substances that can prevent or slow down the activity of other molecules. In drug development, inhibitors are designed to target specific proteins involved in disease processes. For example, kinase inhibitors are used to treat cancer by blocking the activity of kinases that promote cell growth and survival.

---

XIAP

X-linked inhibitor of apoptosis protein

XIAP is a protein that inhibits programmed cell death (apoptosis). It plays a crucial role in regulating the balance between cell survival and death. Cancer cells often overexpress XIAP to evade apoptosis, making it a potential therapeutic target.

---

Ligands

Molecules that bind to receptors or other target sites

Ligands are molecules that can attach to specific targets within cells or tissues. In drug development, ligands are designed to interact with target proteins and modulate their activity. For example, drugs targeting cancer cells often act as ligands that inhibit the growth-promoting activity of certain receptors.

---

CSLP43

Chemical name for a RIPK2 inhibitor

CSLP43 is a chemical compound that has been identified as an inhibitor of RIPK2. Further research is needed to fully understand its mechanism of action and therapeutic potential.

---

GSK583

Chemical name for a RIPK2 inhibitor

GSK583 is a chemical compound that has been identified as an inhibitor of RIPK2. Further research is needed to fully understand its mechanism of action and therapeutic potential.

---

WEHI-345

Chemical name for a RIPK2 inhibitor

WEHI-345 is a chemical compound that has been identified as an inhibitor of RIPK2. Further research is needed to fully understand its mechanism of action and therapeutic potential.